Floatz logo

Tarlatamab

Large Cell Neuroendocrine Carcinoma of the Lung

University of Arizonamonoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Large Cell Neuroendocrine Carcinoma of the Lung cohort.

Asset / SponsorPhaseRating
Abemaciclib
Case Comprehensive Cancer Center
Phase 2B
Pembrolizumab
Ochsner Health System
Phase 2CCC
68Ga-NOTA-AE105
Rigshospitalet, Denmark
Phase 2CCC
[203Pb]Pb-MP0712
Molecular Partners AG
Phase 1/2CCC
[212pb]pb-mp0712
Molecular Partners AG
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Tarlatamab is also rated in:

small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
medullary thyroid gland carcinomaDormant
B
Indicative ·
60 / 100
View asset →
neuroendocrine carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →